Open Research Trials at Sibley Memorial Hospital
Please contact Jackie Lobien at (301) 896-3122 or by email firstname.lastname@example.org to learn about the clinical trials offered at Sibley.
NCIC CTG MA.32: A Phase III Randomized Trial of Metformin versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
NSABP B-43: A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy
NSABP B-47: A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
S1007: A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER-2 Negative Breast Cancer with Recurrence Score (RS) of 25 or Less
WRAMC 07-20029: A Prospective, Randomized, Single-Blinded, Multi-Center Phase II Trial of the HER2/neu Peptide GP2 + GM-CSF Vaccine versus GM-CSF Alone in HLA-A2+ OR the Modified HER2/neu Peptide AE37 + GM-CSF Vaccine versus GM-CSF alone in HLA-A2- Node-Positive and High Risk Node-Negative Breast Cancer Patients to Pre
CALGB 80702: A Phase III trials of 6 versus 12 treatment of Adjuvant Treatment of Adjuvant Folfox plus Celecoxib or Placebo for patient with Resected Stage III Colon Cancer.
J0874 _ I 150709: A Phase I study of the mTOR inhibitor Temsirolimus in combination with the HDAC inhibitor Vorinostat in patients with metastatic prostate cancer.
NA_00049775: Phase I/II study of safety and efficacy of Muscadine Plus (MDX) in men with prostate cancer: A randomized dose-finding study of the effects of two doses of MPX capsule on rising prostate-specific antigen in men following initial therapy for prostate cancer
NA_00046780: Efficacy and Safety of oral Kanglaite (KLTc) Gelcap in Men with Prostate Cancer: Randomized, Dose-Ranging Study of the Effects of KLTc Gelcap (3 or 6 capsules four times/day) on Prostate Specific Antigen (PSA) Doubling Time Among Men with Rising PSA Level
GOG 0212: A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12 Monthly Cycles of Single Agent Paclitaxel or CT-2103 (IND# 70177) Versus No Treatment Until Documented Relapse in Women with Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer Who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy
GOG 0249: A Phase III Trial Of Pelvic Radiation Therapy Versus Vaginal Cuff Brachytherapy Followed By Paclitaxel/Carboplatin In Patients With High-Risk, Early Stage Endometrial Cancer
GOG 0258: A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma
GOG 0262: A Randomized Phase III Trial of Every-3-Weeks Paclitaxel Versus Dose Dense Weekly Paclitaxel in Combination with Carboplatin with or without Concurrent and Consolidation Bevacizumab (NSC #704865, IND #7921) in the Treatment of Primary Stage III or IV Epithelial Ovarian, Peritoneal or Fallopian Tube Cancer
GOG 0263: A Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation In Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy.
RTOG 0724: A Phase III Randomized study of Concurrent Chemotherapy and Pelvic Radiation Therapy With or Without Adjuvant Chemotherapy In High-Risk Patient With Early-Stage Cervical Carcinoma Following Radical Hysterectomy
CALGB 90802: A Randomized Phase III Trial Comparing Everolimus Plus Placebo Versus Everolimus Plus Bevacizumab for Advanced Renal Cell Carcinoma Progressing After Treatment With Tyrosine Kinase Inhibitors
ECOG E1505: A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (> 4 cm) -IIIA Non-Small Cell Lung Cancer (NSCLC)
SWOG S0819: A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab with or without Concurrent Cetuximab in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
ECOG 5508: Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC
CALGB 30607: A Randomized Phase III, Double- Blind Placebo-Controlled trial of Sunitinib ( NSC# 736511, IND # 74019) As Maintenance Therapy in Non-Progressing Patients Following An Initial Four Cycles Of Platinum-Base Combination Chemotherapy In Advance, Stage IIIB/IV Non-Small Cell Lung Cancer
CALGB 50303: A Phase III Randomized Study of R-CHOP v. Dose-Adjusted EPOCH-R with Molecular Profiling in Untreated De Novo Diffuse Large B-cell Lymphomas
ECOG 1609: A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon α- 2b for Resected High-Risk Melanoma